SEOUL, November 25 (AJP) - Korea Eximbank said Tuesday it will provide 350 billion won (about $237 million) in financing to support Celltrion’s acquisition of Eli Lilly’s biosimilar manufacturing plant in the United States.
The acquisition is aimed at strengthening the Korean drugmaker’s supply chain and expanding its presence in the world’s second-largest biosimilar market. Celltrion earlier said it will spend a total of roughly 1.4 trillion won on acquisition, early operations and later expansion of the plant.
The U.S. market is expected to grow rapidly as patents for blockbuster drugs worth more than 1 trillion won in annual sales expire. Washington’s continued push to lower healthcare costs through greater biosimilar uptake is also driving demand, the company said.
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
Related News
-
Hana Securities: Celltrion to Benefit from Growing Demand for Biosimilars in the U.S., Target Price Set at 310,000 won
Hana Securities has forecasted that Celltrion will continue to grow by expanding its presence in the U.S. biosimilar market. The firm initiated coverage with a 'buy' recommendation and set a target price of 310,000 won.On the 18th, Kim Seon-ah, a researcher at Hana Securities, stated in a report, "The five newly launched products are driving revenue growth, and as the sales proportion of these new products increases, the operating profit margin is also improving." Celltrion's consolidated revenue for the third quarter of this year reached 1.58 trillion won, a 53% increase compared to the same period last year. Operating profit rose to 525.3 billion won, up 74%. Kim noted, "While there is currently no profit contribution due to amortization costs from acquisitions, the contract manufacturing organization (CMO) revenue from Eli Lilly, which began this year, is also contributing to the increased revenue." Hana Securities estimates Celltrion's annual revenue for this year will be 5.85 trillion won, with operating profit projected at 1.9 trillion won. This exceeds the company's guidance of 5.3 trillion won in revenue and 1.8 trillion won in operating profit. Kim emphasized, "A key point to note in the company's performance growth is that direct sales results in the U.S. are being observed in earnest starting this year, driven by the newly launched products. We can expect continued growth as more commercialized products are added in the future." He added, "To expand welfare within a limited budget, the use of biosimilars must be encouraged, and companies with high biosimilar sales in the U.S. will inevitably attract market attention." He also stressed the need to maintain interest in Celltrion, which is solidifying its position and increasing its market share in the U.S. next year.The potential for a reassessment of corporate value due to the expansion of U.S. operations was also highlighted. Kim predicted, "The increase in revenue by 2027 will likely depend on the sales of new products in the U.S., and if Celltrion can confirm high demand for its biosimilars in the U.S. through quarterly results, the stock price could rapidly rise beyond previous peaks."* This article has been translated by AI.
-
Celltrion Strengthens Presence in Brazil's Biosimilar Market
Celltrion has launched three additional biosimilars in Brazil, expanding its local product lineup to ten. The company aims to leverage its existing sales network and market share to facilitate the early adoption of these new products and strengthen its foothold in the Latin American market. On November 5, Celltrion announced that its Brazilian subsidiary released the autoimmune disease treatment 'Coivolma' (active ingredient: ustekinumab) and the bone disease treatment 'Stoboclo' and 'Osenbelt' (active ingredient: denosumab) last month. The newly launched products include Coivolma pre-filled syringes (PFS) in 45 mg and 90 mg, as well as a 130 mg vial, Stoboclo PFS in 60 mg, and Osenbelt in a 120 mg vial. Coivolma is marketed globally under the name 'Stelara,' but a different brand name is used in Brazil to accommodate local language preferences. Coivolma is a biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stoboclo and Osenbelt are biosimilars of denosumab, known as Prolia and Xgeva, respectively. Celltrion plans to utilize its established network of hospitals and healthcare professionals to expand prescriptions for the new products. The strategy focuses on increasing product awareness and enhancing sales and marketing efforts in hospitals and clinics that have previously used Celltrion products. The company also highlighted the market performance of its existing products as a foundation for the new launches. According to Celltrion, its autoimmune disease treatment 'Remsima' (infliximab) holds approximately 50% market share in Brazil's private sector. The breast cancer and stomach cancer treatment 'Herzuma' (trastuzumab) and the blood cancer treatment 'Truxima' (rituximab) have secured around 40% and 30% market shares, respectively. With this launch, Celltrion's total product offerings in Brazil have increased to ten. In the autoimmune disease sector, the addition of the ustekinumab product expands its treatment options alongside existing infliximab, adalimumab, and omalizumab products. The company is also preparing for subsequent launches. Celltrion is working towards the year-end release of the ophthalmic disease treatment 'Idenzelt' (aflibercept) and the autoimmune disease treatment 'Aptozumab' (tocilizumab), which will mark its expansion into the ophthalmic sector in Brazil. A Celltrion representative stated, "We will leverage the customer network and trust built through our existing products to promote the early market entry and prescription expansion of new products, while continuing to launch subsequent products to enhance growth in Brazil and the broader Latin American market."* This article has been translated by AI.
-
Celltrion Unveils World's First 'Quadruple Action' Obesity Drug Candidate, Aiming for Clinical Trials Next Year
Celltrion has revealed the nonclinical results of its obesity treatment candidate that simultaneously stimulates four hormonal pathways, marking it as the world's first 'quadruple action' drug.The company announced on November 4 that it presented the nonclinical research findings for its quadruple action obesity treatment candidate, 'CT-G32/SCO-940,' at the global conference 'TIDES Europe' held in Amsterdam from November 3 to 5. This research was conducted in collaboration with Japan's Sucro Pharma.CT-G32/SCO-940 targets four hormonal pathways—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), glucagon, and amylin—within a single candidate. Based on the disclosed development status, this combination of quadruple action for an obesity treatment is a world first.The presentation included pharmacological results related to receptor-specific cell activity assessments and weight, body composition, and insulin levels in diet-induced obese rats. In evaluations using obese animal models, CT-G32/SCO-940 demonstrated greater weight loss effects compared to the representative triple-action drug, retatrutide, when administered at the same dosage. The company explained that during the weight loss process, the proportion of lean mass reduction, including muscle and bone, was relatively lower than that of the comparison drug. This suggests the potential for effective body composition management alongside weight loss, minimizing muscle loss.The drug also showed effectiveness in reducing excessive blood insulin levels, a common issue among obese patients, indicating its potential to extend beyond obesity treatment to metabolic disease therapy. In primate pharmacokinetic evaluations, the drug exhibited prolonged exposure within the body. Based on this, Celltrion stated that it could develop a once-weekly dosing formulation to enhance patient convenience.Celltrion plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in February 2024. If regulatory reviews proceed smoothly, the company aims to initiate global clinical trials with the first patient dosing in the second quarter of the same year. The company intends to develop CT-G32/SCO-940 as a 'first-in-class' new drug that addresses unmet needs, such as individual efficacy differences seen in existing GLP-1-based treatments and muscle loss during weight loss.A Celltrion representative stated, "We have confirmed the differentiation potential of our core pipeline in nonclinical studies with the world's first quadruple action combination, surpassing existing dual and triple-action drugs. We aim to develop it as a next-generation treatment that encompasses not only weight loss but also improvements in body composition and metabolism."* This article has been translated by AI.